40
Participants
Start Date
January 10, 2019
Primary Completion Date
June 30, 2026
Study Completion Date
July 31, 2026
Normal Saline along with standard treatment
The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
PMZ-1620 along with standard treatment
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
RECRUITING
Indian Spinal Injury Centre, New Delhi
RECRUITING
King George's Medical University, Lucknow
RECRUITING
Rahate Surgical Hospital & ICU, Nagpur
NOT_YET_RECRUITING
KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre, Belagavi
RECRUITING
Institute of Postgraduate Medical Education & Research and SSKM Hospital, Kolkata
Lead Sponsor
Pharmazz, Inc.
INDUSTRY